Exelixis
Tracked across 2 events · 12 articles · First seen Jul 31, 2026 · Last active Aug 12, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Levi & Korsinsky, a securities litigation firm, commenced an investigation into Exelixis, Inc. (Nasdaq: EXEL) concerning potential violations of federal securities laws. The investigation focuses on whether Exelixis made materially false or misleading statements regarding…
Impact: Exelixis is the subject of the investigation. Its shares fell after reporting Q2 revenue below consensus and lowering full-year guidance, and it now faces potential securities litigation.
Aug 10, 2026 · 6 articles
Regulatory
Impact: Exelixis markets CABOMETYX, the reference product to which OMCAZIO is bioequivalent. The approval of a lower-dose alternative could increase competition and pressure its market share.
Jul 31, 2026 · 6 articles
100
Exelixis lowered full-year guidanceExelixis securities...
90
Exelixis reported Q2 revenueExelixis securities...
80
Levi & Korsinsky commenced investigation ExelixisExelixis securities...
70
Bong Go reiterated financial guidance ExelixisExelixis securities...
60
Michael Morrissey made positive statements ExelixisExelixis securities...
ERGEN INTELLIGENCE
Track Exelixis live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard